Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients

Transplantation Proceedings

Volumn 37, Issue 8, 2005, Pages 3527-3530

  Stratta, R J ^a,e   Alloway, R R ^b   Lo, A ^c   Hodge, E E ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Roche Research Laboratories   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 27844561722     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.09.061     Document Type: Conference Paper

References (12)

1. F. Vincenti, R. Kirkman, S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation N Engl J Med 338 1998 161
2. B. Nashan, S. Light, I.R. Hardie Reduction of acute renal allograft rejection by daclizumabDaclizumab Double Therapy Study Group Transplantation 67 1999 110
3. H. Ekberg, L. Backman, G. Tufveson Daclizumab prevents acute rejection and improves patient survival post transplantation 1 year pooled analysis Transplant Int 13 2000 151
4. G.L. Bumgardner, I. Hardie, R.W.G. Johnson Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation Transplantation 72 2001 839
5. F. Vincenti, D. Pace, J. Bimbaum Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation Am J Transplant 3 2003 50
6. N. Ahsan, M. Holman, M.V. Jarowenko Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation Am J Transplant 2 2002 568
7. M. Koch, G. Niemeyer, I. Patel Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation Transplantation 73 2002 1640
8. R.J. Stratta, R.R. Alloway, A. Lo Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients primary endpoint analysis of a multicenter, randomized study Transplantation 75 2003 1260
9. A. Humar, K. Khwaja, T. Ramcharan Chronic rejection The next major challenge for pancreas transplant recipients Transplantation 76 2003 918
10. K.S. Reddy, D. Davies, D. Ormond Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation Am J Transplant 3 2003 439
11. P.S. Rao, D.E. Schaubel, R. Saran Impact of graft failure on patient survival on dialysis a comparison of transplant-naïve and post-graft failure mortality rates Nephrol Dial Transplant 20 2005 387
12. A.C. Gruessner, D.E.R. Sutherland Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003 J.M. Cecka P.I. Terasaki Clinical Transplants 2003 2004 UCLA Immunogenetics Center Los Angeles 21